Translumina Therapeutics Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
- Paid Up Capital ₹ 0.10 M
- Company Age 13 Days
- Open Charges ₹ 201.55 Cr
- Satisfied Charges ₹ 9.65 Cr
About Translumina Therapeutics
Translumina Therapeutics Private Limited (TTPL) is a Private Limited Indian Non-Government Company incorporated in India on 25 January 2025 ( 13 days old ). Its registered office is in New Delhi, Delhi.
The Company's status is Active It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹201.55 Cr. The company has closed loans amounting to ₹9.65 Cr, as per Ministry of Corporate Affairs (MCA) records.
Punita Sharma, Vishal Sharma, Indranil Mukherjee, and One other member serve as directors at the Company.
Company Details
-
LocationNew Delhi, Delhi
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U32509DL2025PTC441712
-
Company No.
441712
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
25 Jan 2025
-
Date of AGM
-
-
Date of Balance Sheet
-
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Who are the key members and board of directors at Translumina Therapeutics?
Board Members (4)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Vishal Sharma | Nominee Director | 25-Jan-2025 | Current |
Punita Sharma | Nominee Director | 25-Jan-2025 | Current |
Indranil Mukherjee | Nominee Director | 25-Jan-2025 | Current |
Vishal Goenka | Nominee Director | 25-Jan-2025 | Current |
Financial Performance of Translumina Therapeutics.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
|
||||||
Revenue from Operations |
|
||||||
Total Assets |
|
||||||
Profit or Loss |
|
||||||
Net Worth |
|
||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Translumina Therapeutics?
Unlock access to Translumina Therapeutics's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹201.55 Cr
₹9.65 Cr
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 140.55 Cr
- Citi Bank N.A : 50.00 Cr
- Icici Bank Limited : 11.00 Cr
Latest Charge Details
Date | Lender | Amount | Status |
---|---|---|---|
12 Jun 2023 | Citi Bank N.A | ₹50.00 Cr | Open |
18 Nov 2022 | Hdfc Bank Limited | ₹2.30 M | Open |
30 Aug 2022 | Icici Bank Limited | ₹11.00 Cr | Open |
20 Apr 2022 | Hdfc Bank Limited | ₹1.61 M | Open |
28 Jan 2022 | Hdfc Bank Limited | ₹140.00 Cr | Open |
How Many Employees Work at Translumina Therapeutics?
Unlock and access historical data on people associated with Translumina Therapeutics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Translumina Therapeutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Translumina Therapeutics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.